Dupixent® (dupilumab) is now approved in India for the treatment of adults with moderate-to-severe atopic dermatitis
Sanofi Healthcare India Pvt. Ltd. has achieved a significant milestone in Indian healthcare with the authorization of Dupixent® (dupilumab) for marketing. This revolutionary drug is designed to aid adults suffering…